Evaluation of immune status against hepatitis B in children with thalassemia major in Egypt: A single center study

Yıl 2012, Cilt: 2 Sayı: 02, 44 - 49, 01.06.2012

Hanan H. Soliman Ibrahim Kabbash A. Mohamed R. El-shanshory Hala M. Nagy Said H. Abdou

https://doi.org/10.5799/jmid.123149

Öz

Objectives: Thalassemic children with repeated blood transfusion are at higher risk of suffering transfusion related infections including hepatitis B virus (HBV). HBV vaccine immunogenicity in several studies showed variable response rates. The aim of this study is to evaluate the immunogenic effect of hepatitis B vaccine in thalassemic children at different age groups. Materials and methods: After ethical approval and informed parent consent, 125 diagnosed thalassemic patients were recruited from the Hematology/Oncology Unit, Pediatric Department, Tanta University Hospital. Patient&#39;s transfusion, and vaccination history, clinical data, and blood samples were obtained. Patient&#39;s sera were stored at -20&deg;C till tested for Anti-hepatitis B surface (anti-HBs) by ELISA. Patients with titers <10 IU were tested for HBs-Ag. Results: Although none of our cases had hepatitis B virus infection, only 20.8% had a protective anti-HBs titer (>10 IU/L). Significantly higher percentage of protected patients (40.1%) were younger than 3 years of age, while age groups above 3years showed a significant trend towards having non protective titers (p=0.003). Anti-HBs titers weren&#39;t correlated to age, ferritin, liver enzymes, and duration of transfusion or number of transfused packs. Conclusion: Protective Anti-HBs titer was reduced after age of 3 years in our patients. So, we recommend screening of thalassemic patients at age of 3 years to evaluate the need of a booster dose.

Anahtar Kelimeler

Thalassemia, HBV, vaccination, immunogenicity

Evaluation of immune status against hepatitis B in children with thalassemia major in Egypt: A single center study

Öz

Anahtar Kelimeler

-

Kaynakça

• Sexana A, Phadke SR. Feasibility of thalassemia control by extended family screening in Indian context. J Health Popul Nutr 2002; 20:31-35.
• El-Beshlawy A, Kaddah N, Moustafa A, et al. Screening for ß-thalassemia carriers in Egypt: Significance of the osmotic fragility test. East Mediterr Health J 2007; 13:224-230.
• Rund D, Rachmilewitz E. ß-Thalassemia. N Engl J Med 2005; 353:1135-1146.
• Bassily S, Hyams K, Fouad R, Samfaan M, and Hibbs R. A high risk of hepatitis C infection among Egyptian blood do- nors: The role of parenteral drug abuse. Am J Trop Med Hyg 52; 1995: 503-505.
• Hauri A, Armstrong G, Hutin Y. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004; 15: 7-16.
• Davis AR, Rosenthal P. Hepatitis B in children. Pediatr Rev 2008; 29:111-120
• Elisofon SA, Jonas MM. Hepatitis B and C in children: current treatment and future strategies. Clin Liver Dis 2006; 10:133- 148.
• El-Gilany AH, El-Fedawy S. Bloodborne infections among stu- dent voluntary blood donors in Mansoura University, Egypt. East Mediterr Health J 2006; 12:742-748.
• Kao JH; Chen DS. Global control of hepatitis B virus infection, Lancet Infect Dis 2002; 2:395-403.
• Kirk GD. Hepatitis B vaccination and liver cancer. In: Stew- art BW, Kleihues P (Eds).World Cancer Report. Lyon: IARC Press, 2003, 144-147.
• Bonanni P, Pesavento G, Bechini A, et al. Impact of universal vaccination programs on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 2003; 21: 685-691.
• Fitzsimons D, François G, Hall A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B mutants. Vaccine 2005; 23:4158-4166.
• World Health Organization. Last update: 3 October 2011, Immunization Profile-Egypt, WHO Vaccine Preventable Dis- eases Monitoring System web site, http://apps.who.int/im- munization_monitoring/en/globalsummary/countryprofilere- sult.cfm?C=egy [accessed Oct 5, 2011]
• Rivkina A, Pharm D, Rybalov S. Chronic hepatitis B: Cur- rent and future treatment options. Pharmacotherapy 2002; 22: 721-737.
• But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twen- ty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report. Vaccine 2008; 2; 26:6587-6591.
• Saberifiroozi M, Gholamzadeh S, Serati AR. The long-term immunity among health care workers vaccinated against hepatitis B virus in a large referral hospital in southern Iran. Arch Iran Med.2006; 9:204-207.
• Saraswat S, Banerjee K, Chaudhury N, et al. Post transfu- sion hepatitis type B following multiple transfusions of HBsAg negative blood. J Hepatol 1996; 25:639-643.
• Chang MH. Impact of hepatitis B vaccination on hepatitis B disease and nucleic acid testing in high-prevalence popula- tions. J Clin Virol 2006; 36: 45-50.
• Dentico P, Buongiorno A, Volpe A, Zavoianni D, De Mattia D, Sabato V. Long term persistence of anti-HBs after hepa- titis B immunization in thalassemic patients. Infection 1992; 20:276-278.
• Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10 year follow-up. J Infect Dis. 1999; 179:1319-1325.
• Peces R, Laures AS. Persistence of immunologic memory in long-term hemodialysis and healthcare workers given hepa- titis B vaccine: Role of a booster dose on antibody response. Nephron 2001; 89: 172-176.
• Azarkeivan A, Karimi G, Shaiegan M, Maghsudlu M, Tab- baroki A. Antibody titration and immune response of Iranian beta-thalassemic patients to hepatitis B virus vaccine (boost- er effect). Pediatr Hematol Oncol 2009;26:195-201.
• Vahidi AA, VaresVazirian M, Shamsadini A, et al. Determina- tion of hepatitis B surface antibody titer in vaccinated chil- dren with major thalassemia in Kerman, Iran. Iran J Immunol 2006; 3:30-34.
• Sharifi Z, Milani S, Shooshtari M. Study on efficacy of hepa- titis B immunization in vaccinated beta thalassemia children in Tehran. Iran J Pediatric 2010; 20: 211-215.
• Mokhles M, El Ashry R, Sedky M , et al. Long Term Efficacy of Hepatitis B Vaccine among High Risk Multiple Blood Transfu- sion Children in Egypt J Appl Sci Res. 2009; 5:2504-2510
• Li H, Li RC, Liao SS, Yang JY, Zeng XJ, Wang SS. Persis- tence of hepatitis B vaccine immune protection and response to hepatitis B booster immunization. World J Gastroenterol 1998;4: 493-496.
• Samandari T, Fiore A, Negus S, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan chil- dren and adolescents vaccinated during infancy. Pediatrics 2007; 120: e373-e381
• El Ghandour S, El Sayed H, Abdel Hamid A, Gad S. Effective- ness of Hepatitis B Vaccination in Egyptian infants in Ismailia Governorate. Suez Canal University Med J 1998; 1:123-130.
• Ocak S, Kaya H, Cetin M, Gali E, Ozturk M. Seroprevalence of hepatitis B and hepatitis C in patients with thalassemia and sickle cell anemia in a long-term follow-up. Arch Med Res 2006; 37:895-898
• El Gawhary S, Omar N, Abdel Rahman L, Mahmoud M. He- patic viruses screening in multitransfused Egyptian thalas- semia patients. J Arab Child 2009;20:193-202.